



Characterization and Functional Test of Canine Probiotics

Hyun-Jun Jang¹, Seungwoo Son^{2,3}, Jung-Ae Kim^{1,4}, Min Young Jung¹, Yeon-jae Choi¹, Dae-Hyuk Kim^{1,4,5}, Hak Kyo Lee^{2,3}, Donghyun Shin^{2,3*} and Yangseon Kim^{1*}

¹ Department of Research and Development, Center for Industrialization of Agricultural and Livestock Microorganisms, Jeongeup-si, South Korea, ² Department of Agricultural Convergence Technology, Jeonbuk National University, Jeonju-si, South Korea, ³ The Animal Molecular Genetics & Breeding Center, Jeonbuk National University, Jeonju-si, South Korea, ⁴ Department of Bioactive Material Sciences, Jeonbuk National University, Jeonju-si, South Korea, Biology, Institute for Molecular Biology and Genetics, Jeonbuk National University, Jeonju-si, South Korea

Probiotics can modulate the composition of gut microbiota and benefit the host animal health in multiple ways. *Lactic acid bacteria* (LAB), mainly *Lactobacillus* and *Bifidobacterium* species, are well-known microbes with probiotic potential. In the present study, 88 microbial strains were isolated from canine feces and annotated. Among these, the four strains CACC517, 537, 558, and 566 were tested for probiotic characteristics, and their beneficial effects on hosts were evaluated both *in vitro* and *in vivo*; these strains exhibited antibiosis, antibiotic activity, acid and bile tolerance, and relative cell adhesion to the HT-29 monolayer cell line. Byproducts of these strains increased the viability and decreased oxidative stress in mouse and dog cell lines (RAW264.7 and DH82, respectively). Subsequently, when the probiotics were applied to the clinical trial, changes in microbial composition and relative abundance of bacterial strains were clearly observed in the experimental animals. Experimental groups before and after the application were obviously separated from PCA analysis of clinical results. Conclusively, these results could provide comprehensive understanding of the effects of probiotic strains (CACC517, 537, 558, and 566) and their industrial applications.

Keywords: canine, probiotics, Lactobacillus, Bifidobacterium, feed additives

INTRODUCTION

According to the 2001 definition by the World Health Organization (WHO), probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host (Hotel and Cordoba, 2001). Since Metchnikoff found and proposed the concept of probiotics for the first time more than a century ago (Podolsky, 2012), many different microorganisms have been considered as probiotics; these microorganisms are generally classified as lactobacilli, bifidobacteria, other lactic acid bacteria (LAB), and non-lactic acid bacteria (Holzapfel et al., 2001; Nagpal et al., 2012; Khalighi et al., 2016). In the interaction between host and probiotics, the mechanisms are generally categorized as act on competition between probiotics and pathogenic organisms for an adhesion site or a nutrient compound, synthesis of antimicrobial compounds by probiotics, and modulation of the host immune system. Collectively, these modes of action are considered when screening novel probiotic strains (Shokryazdan et al., 2017; Singh et al., 2018). The beneficial effects of probiotics during the interaction have been reported to contribute to intestinal health in hosts by regulating gut microbiota, stimulating and developing the immune system, activating and enhancing nutrient metabolism, and preventing and attenuating various diseases

OPEN ACCESS

Edited by:

Abelardo Margolles, Consejo Superior de Investigaciones Científicas (CSIC), Spain

Reviewed by:

Huaxi Yi, Ocean University of China, China Neeta Agarwal, Indian Veterinary Research Institute (IVRI), India

*Correspondence:

Donghyun Shin sdh1214@gmail.com Yangseon Kim yangseon@cialm.or.kr

Specialty section:

This article was submitted to Food Microbiology, a section of the journal Frontiers in Microbiology

Received: 04 November 2020 Accepted: 17 February 2021 Published: 08 March 2021

Citation:

Jang H-J, Son S, Kim J-A, Jung MY, Choi Y-j, Kim D-H, Lee HK, Shin D and Kim Y (2021) Characterization and Functional Test of Canine Probiotics. Front. Microbiol. 12:625562. doi: 10.3389/fmicb.2021.625562

1

such as digestive disorders, infectious diseases, cancer, and allergies (Michail et al., 2006; Yadav et al., 2008; Kumar et al., 2009, 2010, 2012; Manoj et al., 2009; Nagpal et al., 2012). The commercial potential of probiotics has been growing in a wide range of industrial fields, including food, feed, dairy, fermentation, and pharmaceuticals (Song et al., 2012; El Hage et al., 2017; Sharma and Im, 2018).

Dogs have been regarded as companion animals for thousands of years. Research on canine probiotics can be meaningful not only for dog health but also for human health, as there is interaction between dogs and their owners (Grzeskowiak et al., 2015). 16S rRNA sequencing revealed that various lactobacilli, including L. acidophilus, L. fermentum, L. rhamnosus, L. salivarius, L. murinus, L. reuteri, L. animalis, L. sanfranciscensis, and L. paraplantarum, were prevalent in all parts of the canine GIT (Beasley et al., 2006; Ritchie et al., 2008; Suchodolski et al., 2008; Tang et al., 2012; Silva et al., 2013). In addition, bifidobacteria of both animal- (B. pseudolongum and B. animalis) and human-origin (B. catenulatum and B. bifidum) have been found in canine feces (Kim and Adachi, 2007; Lamendella et al., 2008; Bunesova et al., 2012). However, functional studies of canine probiotics are rare. In this study, we isolated novel probiotics from dogs and characterized them both in vitro and in vivo. The findings of this study can contribute to the establishment of an integrated model for characterizing novel probiotics, and the characterized probiotics may have potential for use in industrial fields related to dogs.

MATERIALS AND METHODS

Animal Care

The Institutional Animal Care and Use Committee of the Institution approved all animal procedures (JBNU 2020-0139). All methods were performed in accordance with the relevant guidelines and regulations outlined in this protocol.

Isolation of Bacterial Strains From Canine Feces

Feces were collected from six dogs (mean \pm SD age, 6.5 \pm 2.65 months; the ratio of male to female, 2:1; body weight, 13.08 \pm 8.53 kg). All dogs were privately owned and had indoor access. One gram of each fecal sample was processed by crushing and suspending in 10 mL physiological saline, followed by homogenization. For enumeration, a 10 times dilution series of each homogenate was prepared using sterile saline solution and 0.1 mL of the samples were spread on modified MRS (mMRS,de Man, Rogosa, and Sharpe with 0.05% cysteine-HCl agar), BS (Bifidobacterium Selective) agar plate then incubated in anaerobic atmosphere (5% hydrogen and 5% carbon dioxide, and 90% nitrogen) at 37°C for 48 h to obtain single colonies. Subsequently, each colony was sequenced using 16S rRNA gene sequencing method. The annotated 88 bacterial strains were screened by our standard screening procedures. From the screening, Bifidobacterium longum subsp. longum CACC517, Pediococcus acidilactici CACC537, Lactobacillus plantarum subsp. plantarum CACC558, and Lactobacillus paracasei subsp.

tolerans CACC566 were selected for further analysis. As a reference strain, *Lactobacillus rhamnosus GG* ATCC53013 was obtained from Korean Collection for Type Cultures¹.

16S rRNA Gene Amplification and Sequencing

Briefly, 16S rRNA gene of the isolated bacterial strains were amplified using the universal primers 27F (5'-AGA GTT TGA TCC TGG CTC AG-3') and 1492R (5'-GGT TAC CTT GTT ACG ACT T T-3') (Lane, 1991). The PCR reaction was performed using a high-fidelity polymerase (AccuPrime Taq DNA Polymerase System, Invitrogen, Carlsbad, CA, United States) in a Biometra GmBH PCR machine (Göttingen, Germany), according to the manufacturer's instructions. The amplicons for 16S rRNA were sequenced using the primers 785F (5'-GGA TTA GAT ACC CTG GTA-3') and 907R (5'-CCG TCA ATT CMT TTR AGT TT-3').

Phylogenetic Analysis

Gene fragments were assembled using the SeqMan program (Lasergene software V7, DNASTAR, United States) and reference gene sequences were compared with gene sequences available in GenBank DNA databases² and Ribosomal Database Project (RDP) using BLAST (Altschul et al., 1990). Phylogenetic analysis of the 16S rRNA genes was performed using Molecular Evolutionary Genetic Analysis software, Version 7 (Kumar et al., 2016). Evolutionary relationships were constructed using the maximum likelihood method based on bootstrapping (Tamura and Nei, 1993).

Genome Sequencing, Annotation, and Comparison Genomics

DNA from each of the four strains was extracted using a DNeasy UltraClean microbial kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Whole-genome shotgun sequencing of DNA samples of the four strains was carried out using PacBio SMRT sequencing technology. The recently described hierarchical genome assembly process (HGAP, v3.0) was applied to assemble the genomes of the four strains (Hong et al., 2009) and the final assemblies ranged from 2.0 Mb to 3.23 Mb in one contig (Supplementary Figure 1 and Table 1). The genome sequence (ASM2650v1) of the reference strain (Lactobacillus rhamnosus GG ATCC53013) was acquired from NCBI GenBank and compared with the four strains isolated in this study. The genome sequences of the four strains were annotated using Prokka (v1.13) for genomic annotation (Seemann, 2014). The protein-coding sequences of the five strains were predicted and EggNOG (v2.0.1) annotation was carried out using EggNOG-mapper (Huerta-Cepas et al., 2015). The proteincoding sequences were predicted and categorized based on the COG database (v2.0) in Prokka results; the results are shown in Table 1. To evaluate the genetic relatedness among all 5 strains, including the reference strain, average nucleotide identity (ANI)

¹https://kctc.kribb.re.kr/En/Kctc

²https://www.ncbi.nlm.nih.gov

 $\ensuremath{\mathsf{TABLE 1}}\xspace$] Genome information of five used strains (Four stains form this study and One from NCBI).

Strains	ATCC53103	CACC517	CACC537	CACC558	CACC566
Genome size (bp)	3,010,111	2,281,664	2,035,984	3,250,114	3,123,521
GC (%)	46.7	59.8	42.0	44.6	46.3
CDS	2,832	1,835	1,897	3,030	2,984
tRNA	57	56	56	68	59
rRNA	15	12	15	16	15
Average nucleotide identity	-	64.46	66.20	65.80	77.47

was calculated using the JSpecies webserver (Richter et al., 2015). The nucleotide sequences of all five strains were first annotated using Prokka (Seemann, 2014) to obtain GFF formatted files, which were used to calculate the core genes. The core, accessory, and strain-specific genes were calculated using gene information from the Prokka result (**Figure 1B**).

Acid and Bile Salt Tolerance

To evaluate the tolerance of bacterial strains under low pH and high bile salt concentration, the stimulation of GIT was determined in the present study using a previously described procedure with modifications (Liong and Shah, 2005). For assessing the tolerance of microbial strains to acidic conditions, mMRS, BL (Bifidobacterium spp. culture medium) broth was adjusted to pH 2.5 (treatment) and 6.5 (control) using 1 M HCl. Next, overnight cultured isolates (approximately 1×10^7 CFU/mL) were added to each pH-adjusted medium and incubated for 2 h at 37°C (CACC517, 537, 558, and 566) without shaking, respectively. Bile tolerance of the strains was determined on the basis of growth in mMRS and BL broth with 0.3% and 1% oxgall (Difco, United States) for 2 h, using the same incubation temperatures and conditions described earlier for acid tolerance. All experiments were carried out under anaerobic conditions. After incubation, $10 \times$ serial dilutions of the cultures were spread on agar plates, followed by 24 h of incubation at 37°C. Acid and bile tolerance were evaluated by enumeration of viable colonies, and each assay was performed in triplicate. In both cases, survival was calculated using the following formula (Kim et al., 2019):

$$Survivability (\%) = \frac{TreatmentCFU/ml}{ControlCFU/ml} \times 100$$

Antibacterial Analysis

Strains were evaluated for antibacterial activities against economically important enteropathogenic microorganisms, using a previously described disk diffusion method (Tagg and McGiven, 1971) with slight modifications. The following seven enteropathogenic bacteria were used as indicators of antibacterial activity: *Salmonella* Typhimurium NCCP 10438, *Salmonella* Enteritidis NCCP 14546, *Salmonella* Derby NCCP 12238, *Escherichia coli* K99 KCTC 2617, *Yersinia enterocolitica* NCCP 11129, *Yersinia pseudotuberculosis* NCCP 11125, and *Clostridium difficile* JCM1296. In brief, pathogenic strains were initially grown on appropriate media: *E. coli* was grown on Luria Bertani agar (LB), *Salmonella* spp. on Salmonella and Shigella agar (SSA), *and Yersinia* spp. on Brain Heart Infusion (BHI) agar at 30°C and 37°C for 20 h. Diffusion disks of 8 mm diameter were appropriately overlaid on the agar and 1×10^6 CFU/mL of the culture suspensions were dispensed onto the disks. The plates were incubated at 30°C and 37°C for 24 h and the diameters of the inhibition zones around each disk were measured (Kim et al., 2019).

Antibiotic Sensitivity

The sensitivities of the isolated microbial strains to a set of antibiotics were assessed using the E-test minimum inhibitory concentration (MIC) method (E-test bio Merieux BIODISK, France) as previously described (Hummel et al., 2007), with some modifications. A total of 11 antibiotic strips impregnated with amoxicillin, ampicillin, clindamycin, gentamicin, kanamycin, metronidazole, tetracycline, vancomycin, and erythromycin at minimum inhibition concentrations (MIC) ranging from 0.016 to 256 µg/ml, and imipenem and trimethoprim-sulfamethoxazole at minimum inhibition concentrations (MIC) ranging from 0.016 to 32 μ g/ml were used to test the target strains. Fresh samples of target strains were spread onto agar plates containing mMRS (CACC537,558 and 566), BS (CACC517) (Difco, United States), and the E-test strips were laid on the agar; the plates were incubated at 37°C for 24 h in anaerobic condition. To determine antibiotic sensitivity, the MIC was considered as the antibiotic concentration at which dense colonial growth intersected the strip. Tests were performed in triplicate for each strain for optimization (Amin et al., 2009; Kim et al., 2019).

Host Cell Adhesion Assay

The ability of microbial cells to adhere to the intestinal lining was determined using HT-29 colonic carcinoma cells derived from the human small intestine, according to a previous report with slight modifications (Kim et al., 2019). Monolayers of HT-29 cells were prepared in DMEM (Sigma, United States) supplemented with 10% fetal bovine solution (FBS) (Sigma, United States) in 24-well tissue plates (BD Biosciences, San Jose, CA, United States) at a concentration of 1×10^5 cells/well. To test the abilities of the strains for adhesion to host cells, HT-29 cells were incubated with 2×10^7 CFU/mL of a cultured strain for 2 h at 37° C with 5% CO₂. After incubation, the HT-29 cells were aspirated and washed three times with $1 \times$ PBS to remove unbound microbial cells. Adherent cells were detached and appropriate dilution series were prepared, followed by enumeration of viable colonies on appropriate agar plates in triplicate.

Effectiveness Test for Host Cell Viability

Raw264.7 and DH82 cells were seeded at a density of 1×10^3 cells/well in separate 96 well plates and incubated for 24 h at 37°C with 5% CO₂. Cell viability was determined using the WST-1 Assay Kit (Enzo, United States). The bacterial strains were cultured for 20 h at 37°C and then adjusted the number of cells (approximately 1×10^8 CFU/mL). The bacterial culture was centrifuged at 8,000 rpm at 4°C for 10 min to obtain a supernatant. 10 μl of the supernatant



was added to the cells and further incubated for 4 h at 37°C with 5% CO₂. The treated bacterial cells were diluted in a 10-fold dilution series. After that, the cells were incubated with 10 μl WST-1 reagent for 3 h before

harvesting at the indicated time points. Absorbance was measured at both 450 nm and 650 nm (as a reference) using a UV-spectrophotometer (Tecan, Swiss) according to the manufacturer's instructions.

Test for Inhibitory Effect on Nitric Oxide Production (NO) in Host Cells

Measurement of NO production RAW264.7 and DH82 cells were seeded at a density of 1×10^3 cells/well in separate 96 well plates and incubated for 24 h at 37°C with 5% CO₂. The medium in each well was aspirated and replaced with fresh FBS-free DMEM. The bacterial strains were cultured for 20 h at 37°C and then adjusted the number of cells (approximately 1×10^8 CFU/mL). The bacterial culture was centrifuged at 8,000 rpm at 4°C for 10 min to obtain a supernatant. The treated supernatant was diluted in a 10-fold dilution series. Each diluent was adjusted to the volume of 100 µl with DMEN and incubated with host cells for 1 h at 37°C with 5% CO₂. After that in the incubated cells were treated with 500 ng/ml lipopolysaccharide (LPS) for 24 h at 37°C with 5% CO₂. The presence of nitrite in cell culture media was determined using the Griess Reagent System (Promega, Madison, WI, United States) according to the manufacturer's instructions. Briefly, 50 µl of cell culture medium with an equal volume of Griess reagent in a 96-well plate was incubated at room temperature for 10 min. Then, the absorbance was measured at 540 nm. The amount of nitrite in the media was calculated using the sodium nitrite (NaNO₂) standard curve.

Clinical Trial

This study used data from three Korean animal hospitals, and 37 dogs that were privately owned and had indoor access were recruited. Thirty-seven dogs (mean \pm SD age, 62.95 \pm 47.00 months; the ratio of male to female, 1.64:1; body weight, 5.73 ± 3.25 kg) were randomly grouped into four experimental groups (Supplementary Table 2). Each bacterial strain was cultured in mMRS and BL broth under anaerobic condition (5% hydrogen and 5% carbon dioxide, and 90% nitrogen) at 37°C for 48 h and then lyophilized. The probiotic products consisted of 5% fructo-oligosaccharide, 10% skim milk, 15% trehalose, 0.5% glycerin, 1% NaCl, and one of the following bacterial strains: CACC517, CACC537, CACC558, and CACC566. Each experimental group was administered 0.2 g probiotic product, including 10⁸ bacteria, every day for 4 weeks. In detail, the powder of 0.2 g probiotic product was individually sealed in a medicine plastic bag. The powder was dissolved in 1 ml water and fed using a 1 ml syringe. No significant adverse symptoms were reported during the clinical trial. Blood and fecal samples were collected from the dogs before feeding the probiotic products and at 4 weeks after feeding the probiotic products. The blood samples were analyzed using complete blood count (CBC) and electrolyte tests according to standard protocols.

Microbial Community Analysis Using 16S rRNA Sequencing

DNA was isolated from the fecal samples, collected before and after the clinical trial in dogs, using Epi-center DNA isolation kits. We extracted approximately 900 ng of DNA from each sample. DNA quality was confirmed using a Bioanalyzer with an Agilent RNA 6000 Pico Kit (Agilent, Santa Clara, CA, United States). All samples from the reservoir were prepared using the 16S library preparation protocol and the Nextera XT DNA index kit (Illumina, San Diego, CA, United States) to target the V3-V4 variable regions of the 16S rRNA gene. We quantified the library by real-time PCR using a CFX96 real-time system (BioRad, Hercules, CA, United States). Before sequencing, all 54 samples passed a QC test. Samples were loaded onto a MiSeq reagent cartridge (Illumina) and then onto the instrument. Automated cluster generation was performed and a 300 bp single-end sequencing was performed. The resulting sequence reads were equally distributed across the samples. The Illumina MiSeq technology can generate up to 107 sequences in a single run (Kuczynski et al., 2012). Then, quantitative insights into microbial ecology (QIIME) then takes the instrument output and generates useful information about the community in each sample (Caporaso et al., 2010).

We divided the process into upstream and downstream stages. Sample identifier, barcode, and primer sequence information were required for the upstream stage of the QIIME workflow. This processing step combines sample demultiplexing, primer removal, and quality filtering. The first step in the upstream stage is the removal of the barcode sequence. During PCR amplification, some of the amplified sequences can be produced from multiple parent sequences, generating chimeric sequences. Therefore, we identified chimeric sequences in FASTA files from the GREENGENES database (DeSantis et al., 2006) and vsearch (Rognes et al., 2016). Then, we removed the identified chimera sequences from the FASTA files. The next step is clustering the preprocessed sequences into operational taxonomic units (OTUs), which in traditional taxonomy represent groups of organisms defined by intrinsic phenotypic similarity that constitute candidate taxa (Caporaso et al., 2010). For DNA sequence data, these clusters are formed based on sequence identity. In other words, sequences are clustered together if they are more similar than a user-defined identity threshold, presented as a percentage (s). This threshold level is traditionally set at 99% sequence similarity, conventionally assumed to represent bacterial species (Drancourt et al., 2000). An openreference OTU picking process, in which reads were clustered against a reference sequence collection, was carried out and any read that did not hit the reference sequence collection was subsequently clustered de novo (Navas-Molina et al., 2013). PCA analysis was performed before and after probiotic treatment (Figure 5B). Multi-level taxonomic abundance was extracted using QIIME and Student's t-test (paired) was used to detect differentially abundant microbiota by comparing the relative abundance between samples collected before and after probiotics treatment (Figure 5A and Table 4). For the consideration of different reads generated, proportion of read count was used instead. We calculated species richness for a given number of individual samples with rarefaction curves using R package (BiodiversityR) (Figure 6).

Principal Component Analysis (PCA)

All values, including the results of CBC and electrolyte tests, were imported into SIMCA-P (version 14.1, Umetrics Inc., Kinnelon, NJ, United States) for multivariate statistical analysis to examine intrinsic variations in the data set. These data were scaled using cantered unit variance scaling prior to the PCA. PCA score plots were used to interpret the intrinsic variation in the data.

Statistical Analysis

Statistical evaluation of the data was performed using analysis of variance with the general linear model for randomized complete block design. All treatments were performed in triplicate, and Tukey's HSD test was applied to define mean differences between specific treatments. The statistical significance (P < 0.05, P < 0.01, or P < 0.001) of the differences was determined. All analyses were conducted using JMP 14.3.0 (SAS Institute Inc. NC, United States).

RESULTS

Taxonomic Assignment and Probiotics Identification

In this study, over 36 species isolated from the feces of 6 dogs were identified using 16S RNA sequencing. A total of 88 bacterial strains were isolated and probiotic candidates were selected through prescreening (data not shown). Among these strains, four were further studied for probiotic characterization; these included *Bifidobacterium longum* subsp. *longum* CACC517, *Pediococcus acidilactici* CACC537, *Lactobacillus plantarum* subsp. *plantarum* CACC558, and *Lactobacillus paracasei* subsp. *tolerans* CACC566 (Figure 1A).

Probiotics Characterization

Genomic Structure and Genetic Feature

Whole genome sequences of the strains CACC517, CACC537, CACC558, and CACC566 were uploaded to NCBI with accession IDs PRJNA599536, PRJNA601629, PRJNA601672, and PRJNA601660, respectively. The total genome sizes of the four strains (CACC517, CACC537, CACC558, and CACC566) were 2.282 Mb, 2.036 Mb, 3.25 Mb, and 3,124 Mb, respectively (Table 1 and Supplementary Figure 1). The G ++ C content of the genomes of these strains ranged from 42.0% to 59.8%. In addition, genome annotation using the eggNOGmapper (Huerta-Cepas et al., 2015) revealed that the sequenced genomes consisted of 1,835 (CACC517), 1,897 (CACC537), 3,030 (CACC558), and 2,984 (CACC566) coding sequences. Carbohydrate transport and metabolism (G) (10.23%) and amino acid transport and metabolism (E) (9.44%) accounted for the largest proportion of protein coding categories in strain CACC517 (Table 2). The largest proportion of protein coding categories in CACC558 strains were Transcription (K) (9.7%) and Carbohydrate transport and metabolism (G) (8.29%). The largest proportion of protein coding categories in CACC566 and CACC537 were Carbohydrate transport and metabolism (G) (10.02%) and Transcription (K) (8.5%) (Table 2). Further, we performed core gene analysis of the five strains, including Lactobacillus Rhamnosus, based on the GFF file. The five strains contained 422 core genes, 1,217 accessory genes (511 genes: four strains shared genes, 314 genes: three strains shared genes, 392 genes: two strains shared genes), and 882 strain-specific genes (**Figure 1B**). Based on these results, we could expect different characteristics of the four strains sharing basic probiotic characteristics.

Acid and Bile Tolerance and Intestinal Adhesion Ability

When acid and bile tolerance were tested at pH 2.5 and 0.3% and 1% bile salts, respectively, CACC517, CACC537, CACC558, and CACC566 showed higher or equivalent survivability at 0.3% and 1% bile salts-treated conditions, but lower survivability at pH 2.5 compared to *Lactobacillus rhamnosus GG* ATCC53103 (LGG), the reference probiotic strain (P < 0.001) (**Figure 2A**). Assessment of the ability for adhesion to the intestinal lining, using the human colonic carcinoma cell line HT-29, revealed that CACC537, CACC558, and CACC566 exhibited superior or equivalent activity, whereas CACC517 showed slightly lower activity (61.7%) compared to LGG (76.3%) (P < 0.05 or P < 0.001) (**Figure 2B**). Thus, these results suggest that the bacterial strains are tolerant to bile salt environments but susceptible to acidic conditions, relative to the reference probiotic strain.

Antibacterial Activity and Antibiotic Sensitivity

The antibacterial activity test against various pathogenic bacteria revealed that all the strains showed antibacterial activity against S. Typhimurium NCCP 10438, S. Enteritidis NCCP 14546, S. Derby NCCP 12238, E. coli K99 KCTC 2617, and Y. pseudotuberculosis NCCP 11125. Additionally, CACC537 and CACC566 exhibited antibacterial activity against Y. enterocolitica NCCP 11129 while CACC517 exhibited antibacterial activity against C. difficile JCM1296. In particular, CACC558 exhibited antimicrobial activity against all the tested pathogenic bacteria (Table 2). Assessment of antibiotic sensitivity for commercial antibiotics demonstrated that all the tested strains were resistant to kanamycin and vancomycin, except CACC517. Additionally, CACC537 showed resistance to imipenem, while both CACC558 and CACC566 exhibited resistance to metronidazole and trimethoprim-sulfamethoxazole (Table 3). Therefore, we supposed that the strains have different spectra of antibacterial activities and antibiotic resistance.

In vitro and *in vivo* Host Responses to Probiotics

Enhancement of Host Cell Viability

To evaluate the enhancement of host cell viability by the byproducts of the probiotic bacterial strains (CACC517, CACC537, CACC558, and CACC566), the different culture media, in which the strains were separately cultured with different seeding densities, were added to murine macrophage cell line (RAW264.7) or canine macrophage cell line (DH82). The viability of the normally cultured host cells (RAW264.7 and DH82) was not significantly different from that of the negative control (medium only) (**Figure 3A**). In case of RAW264.7 cells, the culture media with seeding densities of 10⁷, 10⁶, and 10⁵ CFU/mL of LGG exhibited increased viability compared to the negative control (P < 0.05, P < 0.01, or P < 0.001). All strains showed a superior or equivalent effect on the enhancement of

TABLE 2 Antibacterial activity of the test strains against the indicator s

Strain	Salmonella Typhimurium NCCP 10438	Salmonella Enteritidis NCCP 14546	Salmonella Derby NCCP 12238	<i>E. coli</i> K99 KCTC 2617	Yersinia enterocolitica NCCP 11129	Yersinia pseudotuberculosis NCCP 11125	Clostridium difficile JCM1296
CACC517	++	+	+	+	_	+	+
CACC537	++	++	++	++	++	+++	-
CACC558	++	++	++	+	++	++	++
CACC566	++	++	+	++	+	+++	-

The inhibition zone (mm) around the paper disc containing the microbial cell-free supernatant was classified as ++, > 12–14 mm; +, > 11mm; w (weak), less than 9 mm; -, no inhibition zone.



treatments for 2 h (A) and their ability to adhere to the intestinal lining using the human colonic carcinoma cell line HT-29 (B). A significant difference was determined compared to the reference strain (LGG, *Lactobacillus rhamnosus* GG ATCC53103). *P < 0.05; ***P < 0.001.

TABLE 3 | Minimum inhibitory concentrations (μ g/ml) of antibiotics against the test strains.

Antibiotic	Antibiotic sensitivity					
	CACC517	CACC537	CACC558	CACC566		
Amoxicillin	0.38	3	≥ 0.19	≥1.5		
Ampicillin	0.25	2	≥ 0.094	≥1.5		
Clindamycin	S	0.094	≥ 2	≥0.38		
Erythromycin	0.032	48	≥ 1.5	≥0.25		
Gentamicin	96	0.32	≥ 24	R		
Imipenem	0.25	R	≥ 0.047	≥1.5		
Kanamycin	R	R	R	R		
Metronidazole	1	24	R	R		
Tetracycline	0.38	R	≥ 16	≥1		
Trimethoprim-sulfamethoxazole	4	0.75	R	R		
Vancomycin	0.75	R	R	R		

Quantitative antibiotic sensitivity is expressed as the minimum inhibitory concentration against the microbial strains and classified as R, resistant (\geq 32 and 256 µ.g/ml) or presented as values in bold (weakly tolerant) and regular font (sensitive to the antibiotic).

host cell viability compared to LGG (P < 0.05). However, culture medium with a seeding density of 10⁸ CFU/mL of LGG decreased the viability of RAW264.7 compared to the negative control

(P < 0.05) (upper part of **Figure 3A**). In case of DH82 cells, the culture media with seeding densities of 10^4 , 10^3 , 10^2 , and 10 CFU/mL of LGG did not affect the viability. In addition, the culture medium with a seeding density of 10^4 CFU/mL of CACC517, CACC537, CACC558, and CACC566 did not affect the viability of DH82 cells. However, compared to LGG, the culture media of CACC537 and CACC558 increased cell viability under all seeding conditions. The culture media of CACC517 at seeding densities of 10^3 and 10^2 CFU/mL and CACC566 at a seeding density of 10^2 CFU/mL increased cell viability compared to LGG (lower part of **Figure 3A**). Therefore, we suggest that the byproducts of the bacterial strains can increase host cell viability.

Inhibition of Inflammatory Responses in Host Cells

To evaluate anti-inflammatory activities for host cells mediated by the byproducts of the bacterial strains (CACC517, CACC537, CACC558, and CACC566), host cells were stimulated by lipopolysaccharides (LPS). The culture media, in which the strains were separately cultured with different seeding densities, were added to stimulated RAW264.7 and DH82 cells. The levels of nitric oxide (NO) were measured using the Greiss assay. When LPS and bacterial culture media without any bacteria were simultaneously used to treat the host cells (LPS + media, negative control), the effect of LPS treatment was reduced, with higher NO



levels than the normally cultured cells (RAW264.7 and DH82) and the negative control (P < 0.05, P < 0.01, or P < 0.001) (**Figure 3B**). In case of RAW264.7 cells, culture media with all seeding density conditions of LGG decreased NO production compared to the negative control (P < 0.001). All strains, excluding CACC537 seeded at 10⁵ CFU/mL, showed a superior or equivalent anti-inflammatory effect compared to LGG (P < 0.05, P < 0.01, or P < 0.001) (upper part of **Figure 3B**). In case of DH82 cells, culture media with all seeding density conditions of LGG decreased NO production compared to the negative control (P < 0.001). All strains, excluding CACC517 seeded at 10⁴ CFU/mL, showed a superior or equivalent effect compared to LGG (P < 0.001) (lower part of **Figure 3B**). Therefore, we hypothesized that the byproducts of the bacterial strains can

Feeding Effects in Dogs

To evaluate the physiological effects of the bacterial strains in dogs, 10⁸ CFU/ml of each bacterial strain (CACC517, CACC537, CACC558, and CACC566) was fed to dogs every day for 4 weeks. The blood of individual dogs was sampled before and after feeding. Subsequently, the blood samples were examined

attenuate inflammatory responses and inhibit NO production.

for complete blood count (CBC) and electrolyte tests. In total, 74 samples yielded 1645 values for 13 parameters of the CBC test and 10 parameters of the electrolyte test. The examined data were collectively integrated and analyzed using principal component analysis (PCA). The results of the PCA showed that individual dogs were clearly clustered by before and after bacterial feeding (**Figure 4A**). Moreover, the clusters were strainspecifically separated (**Figure 4B**). These results suggest that the bacterial strains can independently have a direct influence on the physiological status of dogs.

Gut Microbial Diversity Before and After Probiotics Treatment

16S rRNA gene sequencing was used to monitor changes in the microbial community in the fecal samples collected before and after feeding the bacterial strains (CACC517, CACC537, CACC558, and CACC566). The results of 16S rRNA sequencing revealed variability in the microbial composition and relative abundance at several levels in the fecal microbiota of dogs before and after probiotics treatment (P < 0.1) (**Table 4**). In the CACC517 treatment test, the relative abundance of Fusobacteria at the phylum level before and after probiotics



treatment was significantly different. Microbial taxonomy at the order level showed that the relative abundances of Erysipelotrichales and Fusobacteriales before and after probiotics treatment were significantly different, with p-values 0.036 and 0.079, respectively. The 16S rRNA sequencing results of the genera Clostridium and Fusobacterium before and after probiotics treatment were also significantly different. In the CACC537 treatment test, the relative abundance of Bacteroidetes at the phylum level, Bacteroidia at class level, Bacteroidales at order level, Bacteroidaceae at the family level, and Bacteroides at the genus level were significantly different. Microbial taxonomy at the genus level showed that the relative abundance of Bacteroides before and after probiotics treatment was significantly different. In the CACC558 treatment test, the relative abundance of Fusobacteria at the phylum level before and after probiotics treatment was significantly different. Microbial taxonomy at the order level showed that the relative abundance of Coriobacteriales, Erysipelotrichales, and Fusobacteriales before and after probiotics treatment were significantly different. The five families (Clostridiaceae, Coriobacteriaceae, Ervsipelotrichaceae, Fusobacteriaceae, and Fusobacteriaceae) were significantly different before and after probiotics treatment (Figure 5A and Table 4).

Additionally, the 16S rRNA sequencing results of the genera Collinsella and Fusobacterium were significantly different before and after probiotics treatment. In the CACC537 treatment test, there were very few differentially abundant microbiota; only Porphyromonadaceae in the family and Bacteroides in genus were significantly different before and after the treatment. Additionally, we compared between the microbial composition and relative abundance at the genus level for each strain before and after probiotics treatment. In case of *Bifidobacterium*, which included the strain CACC517 and *Lactobacillus*, which includes CACC558, the mean relative abundance and variance decreased after probiotic treatment. Otherwise, the mean relative abundance and variance of *Lactobacillus*, including CACC566 and CACC537, increased after the treatment (**Table 4**).

Principal component analysis of all individual dogs showed that the PCA result was slightly different before and after probiotics treatments; however, it was not different among the strains CACC517, CACC537, CACC558, and CACC566 (**Figure 5B**). As shown in the rarefaction curve figure using all individuals, the number of OTUs was higher after probiotic treatment than before the treatment in CACC517 and CACC537 (**Figure 6**). However, we did not find a clear difference between before and after CACC566 treatment and diversity after CACC558 treatment. Based on this result, it can be seen that CACC517 and CACC537 altered the diversity of the intestinal microbial community.

DISCUSSION

In previous studies, bacteria of the canine gastrointestinal (GI) tract and feces were mainly categorized into five phyla: Firmicutes, Fusobacteria, Bacteroidetes, Proteobacteria, and Actinobacteria (Suchodolski et al., 2008; Honneffer et al., 2017; Coman et al., 2019). To screen functional probiotics in dog, we isolated the probiotic candidates CACC517, CACC537, CACC558, and CACC566 from canine feces and identified them

TABLE 4 | Differentially abundant microbiota before and after probiotics treatment.

Strain	Level	Microbe	Mean		T-test P-value (<0.1)
		_	Before	After	_
CACC517 (B. longum)	Phylum	k_Bacteria; p_Fusobacteria	0.023	0.008	0.078
	Class	k_Bacteria; p_Firmicutes; c_Erysipelotrichi	0.038	0.089	0.036
	Class	k_Bacteria; p_Fusobacteria; c_Fusobacteriia	0.023	0.008	0.078
	Order	k_Bacteria; p_Firmicutes; c_Erysipelotrichi; o_Erysipelotrichales	0.038	0.089	0.036
	Order	k_Bacteria; p_Fusobacteria; c_Fusobacteriia; o_Fusobacteriales	0.023	0.008	0.079
	Family	k_Bacteria; p_Firmicutes; c_Erysipelotrichi; o_Erysipelotrichales; f_Erysipelotrichaceae	0.039	0.091	0.033
	Family	k_Bacteria; p_Fusobacteria; c_Fusobacteriia; o_Fusobacteriales; f_Fusobacteriaceae	0.023	0.009	0.075
	Genus	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Clostridiaceae; g_Clostridium	0.001	0.020	0.079
	Genus	k_Bacteria; p_Fusobacteria; c_Fusobacteriia; o_Fusobacteriales; f_Fusobacteriaceae; g_Fusobacterium	0.023	0.009	0.076
CACC566 (L. paracasei)	Phylum	k_Bacteria; p_Bacteroidetes	0.100	0.229	0.023
paraoaooij	Class	k_Bacteria; p_Bacteroidetes; c_Bacteroidia	0.100	0.229	0.023
	Order	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales	0.100	0.229	0.023
	Family	<pre>k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f Bacteroidaceae</pre>	0.088	0.198	0.095
	Genus	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae; g_Bacteroides	0.088	0.200	0.096
CACC558 (L. plantarum)	Phylum	k_Bacteria; p_Fusobacteria	0.011	0.000	0.073
, ,	Class	k_Bacteria; p_Firmicutes; c_Bacilli	0.130	0.232	0.085
	Class	k_Bacteria; p_Actinobacteria; c_Coriobacteriia	0.032	0.000	0.045
	Class	k_Bacteria; p_Firmicutes; c_Erysipelotrichi	0.049	0.014	0.033
	Class	k_Bacteria; p_Fusobacteria; c_Fusobacteriia	0.012	0.000	0.072
Class k_Bacteria; p Class k_Bacteria; p Order k_Bacteria; p	k_Bacteria; p_Actinobacteria; c_Coriobacteriia; o_Coriobacteriales	0.033	0.000	0.045	
	Order	k_Bacteria; p_Firmicutes; c_Erysipelotrichi; o_Erysipelotrichales	cteria; c_Fusobacteriia 0.012 (acteria; c_Coriobacteriia; 0.033 (0.015	0.034
	Order	k_Bacteria; p_Fusobacteria; c_Fusobacteriia; o_Fusobacteriales	0.012	0.000	0.072
	Order	k_Bacteria; p_Firmicutes; c_Bacilli; o_Lactobacillales	0.116	0.229	0.090
	Family	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Clostridiaceae	0.179	0.061	0.072
	Family	k_Bacteria; p_Actinobacteria; c_Coriobacteriia; o_Coriobacteriales; f_Coriobacteriaceae	0.033	0.000	0.045
	Family	k_Bacteria; p_Firmicutes; c_Erysipelotrichi; o_Erysipelotrichales; f_Erysipelotrichaceae	0.049	0.015	0.034
	Family	k_Bacteria; p_Fusobacteria; c_Fusobacteriia; o_Fusobacteriales; f_Fusobacteriaceae	0.012	0.000	0.072
	Family	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Veillonellaceae	0.004	0.000	0.023
	Genus	k_Bacteria; p_Actinobacteria; c_Coriobacteriia; o_Coriobacteriales; f_Coriobacteriaceae; g_Collinsella	0.027	0.000	0.083
	Genus	k_Bacteria; p_Fusobacteria; c_Fusobacteriia; o_Fusobacteriales; f_Fusobacteriaceae; g_Fusobacterium	0.012	0.000	0.070
CACC537 (P. acidilactici)	Family	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Porphyromonadaceae	0.003	0.001	0.096
	Genus	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Porphyromonadaceae; g_Parabacteroides	0.003	0.001	0.096



FIGURE 5 | Microbial community analysis using 16S rRNA sequencing. Multi-level taxonomic abundance was extracted using QIIME and Student's *t*-test (Paired) was used to detect differentially abundant microbiota by comparing relative abundance between the before and after probiotics treatment states (A) and PCA analysis of before and after probiotics treatment states was performed (B).



using 16s rRNA gene sequencing, which revealed that these candidates belonged to *Lactobacillus* species, *Bifidobacterium* species, and other lactic acid bacteria (LAB), which are considered as probiotics (Holzapfel et al., 2001).

To characterize the genomic information of these four strains, we compared the genomic information of them with LGG (LGG ATCC53103; genomic sequence version. ASM2650v1) and analyzed the genetic basis to identify the characteristics of each strain. The largest proportion of protein coding category in each of the four strains was Carbohydrate transport and metabolism (G). The results of this analysis indicated that the four strains from canine feces in this study were closely related to carbohydrate metabolism. In addition, this result was consistent with a study on changes in dog domestication (Caporaso et al., 2010). Based on the results of EggNog analysis, we found that the categories with the largest variation in gene number were Transcription (K) and Amino acid transport and metabolism (E). Unlike wild wolves, which are carnivorous animals, present-day dogs have a more diverse diet, mainly including food containing starch, fat, and protein (Rowe et al., 1997). We inferred that changes in the domestication process of dogs caused changes in the gut microbiota of dogs. We identified many specific genes in the four strains and clearly correlated differences between the four strains and LGG. We further compared the correlation between *Lactobacillus rhamnosus* and LGG. The results indicated different effects of these four strains on the dog gut system.

The procedures for probiotic characterization have been well established. In terms of safety, functional and technological aspects, acid and bile salt tolerance, adherence to intestinal cells, and production of antimicrobial substances were evaluated using reference strains (Saarela et al., 2000). In our study, the bacterial strains were characterized as probiotics based on comparisons with LGG. LGG is a well-characterized probiotic isolated from the human intestinal tract (Silva et al., 1987) and has shown prominent survivability in the acidic condition and bile of stomach, as well as good adhesion to the human colonic carcinoma cell line HT-29 (Conway et al., 1987; Kim et al., 2019). Based on the comparison between the LGG and each of the isolated bacterial strains, CACC558 showed good bile salt tolerance, adherence to intestinal cells, and ability for inhibition of pathogenic bacteria. Thus, CACC558 can be considered a strong candidate for commercial probiotics.

Previous studies have reported the positive effects of LGG on host health, especially in the GI tract (Tao et al., 2006; Yan et al., 2007; Ciorba et al., 2012). In addition, LGG modulates the host immune system and attenuates LPS-induced inflammatory responses (Zhang et al., 2006; Lee et al., 2012; Fong et al., 2016). In our study, the bacterial strains (CACC517, CACC537, CACC558, and CACC566) showed improved or equivalent effects on host cell viability and inhibition of inflammatory responses compared to LGG, although elaborate optimization of treatment conditions was required in *in vitro* experiment. Interestingly, the bacterial strains exhibited overall superior effects compared to LGG in the canine macrophage cell line (DH82) than in the murine macrophage cell line (RAW264.7). Host preference for probiotics have been studied for their beneficial effects on the host by effectively balancing the microbial environment of the gut and enhancing nutrient digestibility, growth, and immune status (Ripamonti et al., 2011; Chiang et al., 2015; Cui et al., 2017; Dowarah et al., 2017, 2018; Abdou et al., 2018). However, direct comparative studies based on host differences are still limited. Thus, we propose that our results could provide evidence on the effectiveness of host-prefer probiotics, although it should be further studied to understand the specific interactions between a host and probiotic strains.

Currently, probiotic research is extending to a wide range of fields beyond intestinal health care, such as enhancement of immune response, maintenance of homeostasis, and even cancer prevention (Kumar et al., 2010; Kechagia et al., 2013). In this regard, analysis of blood, which is associated with overall host homeostasis and the immune system, can reflect the physiological changes of a subject due to probiotic effects. However, there is no conclusively single parameter to determine the physiological effects of probiotics in blood. Based on the clinical trial for the dogs that were privately owned and had indoor access, blood samples before and after treatments with the probiotics were analyzed by complete blood count (CBC) and electrolyte tests. From the analysis, lymphocyte or chloride was significantly increased after probiotics feeding (P < 0.05) (Supplementary Figure 2) and other blood components generally showed increased trends after treatment (P < 0.5) (Supplementary Figure 3). Lymphocyte number of white blood cell (WBC) reflects immunity and chloride (Cl) level is regarded as a supplementary factor if a healthy of the heart and kidneys are concerned (McClatchey, 2002; Rao et al., 2007). Thus, the increased levels can be considered as a positive clinical sign within normal ranges. Subsequently, we introduced the multicomponent analysis approach and collectively analyzed 23 blood-originated parameters (Supplementary Table 3). PCA showed that the treatment of each strain was obviously clustered between before and after the treatment suggesting an effect of probiotics treatment. Additionally, the individual dog showed relatively broad distribution within the group before treatment or the group after treatment. We supposed that the relatively broad distribution within a cluster reflects various environmental factors and physiological statuses of an individual dog.

The previous studies have reported the alteration of intestinal microbiota by probiotics treatment. For example, Lactobacillus paracasei DG intake increased the relative abundance of Proteobacteria and the Clostridiales genus Coprococcus while it decreased the Clostridiales genus Blautia, Anaerostipes, and Clostridium in human fecal microbiota compared to control group (Ferrario et al., 2014). The ingestion of fermented milk containing Lactobacillus casei Shirota elevated the numbers of Bifidobacterium and Lactobacillus while it reduced the number of Clostridium difficile in the fecal microbiota of the subjects than the placebo group (Nagata et al., 2016). The treatment of Lactobacillus plantarum JDFM LP11 increased the population of lactic acid bacteria in porcine feces (Shin et al., 2019). Recently, It suggested that a single probiotic strain that was appropriately chosen is equivalent or more effective than a multi-strain mixture (McFarland, 2020). In our study, analysis of the fecal samples revealed changes in the microbial composition and relative abundance before and after treatment with the probiotic strains. In case of CACC517 treatment, Erysipelotrichaceae at the family level significantly increased after probiotics treatment. A previous probiotic study showed that the relative abundance of *Erysipelotrichaceae* was lower in broilers supplemented with probiotics than in broilers supplemented with antibiotics (Neveling et al., 2017). Based on these results, we hypothesized that the composition of this family in gut microbiota could be controlled to replace antibiotics in the diet because members of the Erysipelotrichaceae family are closely linked to high immunogenicity and flourish (Neveling et al., 2017). Fusobacterium at the genus level was significantly decreased after probiotics treatment. A previous study reported that Fusobacterium may be associated with inflammatory bowel

disease (Gao et al., 2015). Therefore, it could be presumed that the reduction of Fusobacterium in normal cells by treatment with CACC517 could be helpful in preventing intestinal diseases. We identified significant differences in relative abundance of Bacteroides at the genus level before and after CACC566 treatment in dogs. In a previous human study, probiotics greatly enriched the relative abundance of beneficial bacteria Bacteroides. Previous studies have shown that the decrease in the abundance of *Bacteroides* is closely related to poor health. Moreover, butvrate produced by Bacteroides plays an important role in maintaining the intestinal health of the host, exerting immunity, and antitumor effects (Deng et al., 2020). In addition to these two stains, we confirmed important relative abundance of several microbial flora before and after CACC558 treatment in dogs. Clostridiaceae at the family level decreased after CACC558 treatment, and another study reported that Clostridiaceae was one of three key bacterial families related to the digestion of protein in dogs. Therefore, we believe that CACC558 treatment has a beneficial role in the digestion of protein in the dog gut. Coriobacteriaceae at the family level was significantly reduced after probiotic treatment in dogs, and a previous study reported that Coriobacteriaceae was more frequently detected in patients with Crohn's disease than in healthy subjects (Loh and Blaut, 2012). When dogs were treated with CACC558, the reduction in the abundance of Coriobacteriaceae was predicted to be helpful in preventing chronic inflammatory bowel diseases such as Crohn's disease. Erysipelotrichaceae at the family level significantly decreased after probiotic treatment in dogs. In the case of Fusobacterium at the genus level, this effect of CACC558 in dogs was the same as that of CACC517. The results of CACC517 treatment showed that Fusobacterium at the genus family level was significantly reduced after probiotic treatment in dogs. Interestingly, the effect of CACC558 treatment on Erysipelotrichaceae was the opposite of CACC517. We found that the four candidate strains had diverse effects in terms of extent and directions. We found that Parabacteroides at the genus level were significantly different before and after CACC537 treatment in dogs, and another previous study reported that this microorganism is closely associated with inflamed IBD mucosa (Zitomersky et al., 2013).

Collectively, we reported four novel canine probiotic strains and functional activities for the strains in *in vitro* experiment. We also found that the strains changed clinical parameters in blood and microbial abundance in feces under commercial probiotics feeding conditions. Therefore, our study could contribute to the feasibility of using these strains as probiotics in dogs.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and

REFERENCES

Abdou, A. M., Hedia, R. H., Omara, S. T., Mahmoud, M. A. E., Kandil, M. M., and Bakry, M. A. (2018). Interspecies comparison of probiotics isolated from accession number(s) can be found in the article/**Supplementary** Material.

ETHICS STATEMENT

The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of Jeonbuk National University. Written informed consent was obtained from the owners for the participation of their animals in this study.

AUTHOR CONTRIBUTIONS

DS and YK: conceptualization. H-JJ, DS, and YK: writingoriginal draft preparation. SS, J-AK, MJ, H-JJ, and Y-jC: methodology, investigation, and visualization. H-JJ, SS, and J-AK: formal analysis. D-HK: resources. SS, J-AK, MJ, H-JJ, D-HK and HL: writing-review and editing. All the authors approved the final version of the manuscript.

FUNDING

This research was supported by the Strategic Initiative for Microbiomes in Agriculture and Food grant No. 918002-4, Ministry of Agriculture, Food and Rural Affairs, South Korea.

ACKNOWLEDGMENTS

The authors especially thank Dr. Sung-Ho Lee of WooGene B&G Co., Ltd. for the comments and discussions about pet probiotics.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb. 2021.625562/full#supplementary-material

Supplementary Figure 1 | Genomic structure of the bacterial strains.

Supplementary Figure 2 | The significant changes of blood components before and after the clinical trial.

Supplementary Figure 3 | The trends of blood components before and after the clinical trial.

Supplementary Table 1 | eggNOG-mapper results using five strains available complete genome sequences from NCBI and this study.

Supplementary Table 2 | Information on dogs for clinical trials.

Supplementary Table 3 | The results of the blood chemistry analysis for 37 dogs before and after the clinical trial.

different animals. Vet. World 11, 227–230. doi: 10.14202/vetworld.2018. 227-230

Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local alignment search tool. *J. Mol. Biol.* 215, 403–410. doi: 10.1016/S0022-2836(05) 80360-2

- Amin, M., Jorfi, M., Khosravi, A. D., Samarbafzadeh, A. R., and Farajzadeh Sheikh, A. (2009). Isolation and identification of *Lactobacillus casei* and *Lactobacillus plantarum* from Plants by PCR and detection of their antibacterial activity. *J. Biol. Sci.* 9, 810–814. doi: 10.3923/jbs.2009.810.814
- Beasley, S. S., Manninen, T. J., and Saris, P. E. (2006). Lactic acid bacteria isolated from canine faeces. J. Appl. Microbiol. 101, 131–138. doi: 10.1111/j.1365-2672. 2006.02884.x
- Bunesova, V., Vlkova, E., Rada, V., Rockova, S., Svobodova, I., Jebavy, L., et al. (2012). *Bifidobacterium animalis* subsp. lactis strains isolated from dog faeces. *Vet. Microbiol.* 160, 501–505. doi: 10.1016/j.vetmic.2012.06.005
- Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., et al. (2010). QIIME allows analysis of high-throughput community sequencing data. *Nat. Methods* 7, 335–336. doi10.1038/nmeth.f.303
- Chiang, M. L., Chen, H. C., Chen, K. N., Lin, Y. C., Lin, Y. T., and Chen, M. J. (2015). Optimizing production of two potential probiotic Lactobacilli strains isolated from piglet feces as feed additives for weaned piglets. *Asian Aust. J. Anim. Sci.* 28, 1163–1170. doi: 10.5713/ajas.14.0780
- Ciorba, M. A., Riehl, T. E., Rao, M. S., Moon, C., Ee, X., Nava, G. M., et al. (2012). *Lactobacillus* probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. *Gut* 61, 829–838. doi: 10.1136/gutjnl-2011-300367
- Coman, M. M., Verdenelli, M. C., Cecchini, C., Bela, B., Gramenzi, A., Orpianesi, C., et al. (2019). Probiotic characterization of *Lactobacillus* isolates from canine faeces. J. Appl. Microbiol. 126, 1245–1256. doi: 10.1111/jam.14197
- Conway, P. L., Gorbach, S. L., and Goldin, B. R. (1987). Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J. Dairy Sci. 70, 1–12. doi: 10.3168/jds.S0022-0302(87)79974-3
- Cui, J., Xiao, M., Liu, M., Wang, Z., Liu, F., Guo, L., et al. (2017). Coupling metagenomics with cultivation to select host-specific probiotic microorganisms for subtropical aquaculture. *J. Appl. Microbiol.* 123, 1274–1285. doi: 10.1111/jam.13555
- Deng, X., Tian, H., Yang, R., Han, Y., Wei, K., Zheng, C., et al. (2020). Oral probiotics alleviate intestinal dysbacteriosis for people receiving bowel preparation. *Front. Med. (Lausanne)* 7:73. doi: 10.3389/fmed.2020.00073
- DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., et al. (2006). Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. *Appl. Environ. Microbiol.* 72, 5069–5072. doi: 10.1128/AEM.03006-05
- Ding, W. K., and Shah, N. P. (2007). Acid, bile, and heat tolerance of free and microencapsulated probiotic bacteria. J. Food Sci. 72, M446–M450. doi: 10. 1111/j.1750-3841.2007.00565.x
- Dowarah, R., Verma, A. K., Agarwal, N., Patel, B. H. M., and Singh, P. (2017). Effect of swine based probiotic on performance, diarrhoea scores, intestinal microbiota and gut health of grower-finisher crossbred pigs. *Livestock Sci.* 195, 74–79. doi: 10.1016/j.livsci.2016.11.006
- Dowarah, R., Verma, A. K., Agarwal, N., Singh, P., and Singh, B. R. (2018). Selection and characterization of probiotic lactic acid bacteria and its impact on growth, nutrient digestibility, health and antioxidant status in weaned piglets. *PLoS One* 13:e0192978. doi: 10.1371/journal.pone.0192978
- Drancourt, M., Bollet, C., Carlioz, A., Martelin, R., Gayral, J.-P., and Raoult, D. (2000). 16S ribosomal DNA sequence analysis of a large collection of environmental and clinical unidentifiable bacterial isolates. *J. Clin. Microbiol.* 38, 3623–3630. doi: 10.1128/JCM.38.10.3623-3630.2000
- El Hage, R., Hernandez-Sanabria, E., and Van De Wiele, T. (2017). Emerging trends in "Smart Probiotics": functional consideration for the development of novel health and industrial applications. *Front. Microbiol.* 8:1889. doi: 10.3389/fmicb. 2017.01889
- Ferrario, C., Taverniti, V., Milani, C., Fiore, W., Laureati, M., De Noni, I., et al. (2014). Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. *J. Nutr.* 144, 1787–1796. doi: 10.3945/jn.114.197723
- Fong, F. L. Y., Kirjavainen, P. V., and El-Nezami, H. (2016). Immunomodulation of *Lactobacillus rhamnosus* GG (LGG)-derived soluble factors on antigenpresenting cells of healthy blood donors. *Sci. Rep.* 6:22845. doi: 10.1038/ srep22845

- Gao, Z., Guo, B., Gao, R., Zhu, Q., Wu, W., and Qin, H. (2015). Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. *Mol. Med. Rep.* 12, 6119–6127. doi: 10.3892/mmr.2015. 4124
- Grzeskowiak, L., Endo, A., Beasley, S., and Salminen, S. (2015). Microbiota and probiotics in canine and feline welfare. *Anaerobe* 34, 14–23. doi: 10.1016/j. anaerobe.2015.04.002
- Guo, X., Chen, D. D., Peng, K. S., Cui, Z. W., Zhang, X. J., Li, S., et al. (2016). Identification and characterization of Bacillus subtilis from grass carp (*Ctenopharynodon idellus*) for use as probiotic additives in aquatic feed. *Fish Shellfish Immunol.* 52, 74–84. doi: 10.1016/j.fsi.2016.03.017
- Holzapfel, W. H., Haberer, P., Geisen, R., Bjorkroth, J., and Schillinger, U. (2001). Taxonomy and important features of probiotic microorganisms in food and nutrition. Am. J. Clin. Nutr. 73, 365S–373S. doi: 10.1093/ajcn/73.2.365s
- Hong, Z., Jiexin, W., Zhang, H., Zhigang, S., Yun, J., and Jianfeng, C. (2009). Facile preparation of danazol nanoparticles by high-gravity anti-solvent precipitation (HGAP) method. *Chin. J. Chem. Eng.* 17, 318–323. doi: 10.1016/S1004-9541(08)60210-4
- Honneffer, J. B., Steiner, J. M., Lidbury, J. A., and Suchodolski, J. S. (2017). Variation of the microbiota and metabolome along the canine gastrointestinal tract. *Metabolomics* 13:26. doi: 10.1007/s11306-017-1165-3
- Hotel, A. C. P., and Cordoba, A. (2001). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. *Prevention* 5, 1–10.
- Huerta-Cepas, J., Szklarczyk, D., Forslund, K., Cook, H., Heller, D., Walter, M. C., et al. (2015). eggNOG 4.5: a hierarchical orthology framework with improved functional annotations for eukaryotic, prokaryotic and viral sequences. *Nucleic Acids Res.* 44, D286–D293. doi: 10.1093/nar/gkv1248
- Hummel, A. S., Hertel, C., Holzapfel, W. H., and Franz, C. M. (2007). Antibiotic resistances of starter and probiotic strains of lactic acid bacteria. *Appl. Environ. Microbiol.* 73, 730–739. doi: 10.1128/AEM.02105-06
- Kechagia, M., Basoulis, D., Konstantopoulou, S., Dimitriadi, D., Gyftopoulou, K., Skarmoutsou, N., et al. (2013). Health benefits of probiotics: a review. *ISRN Nutr.* 2013:481651. doi: 10.5402/2013/481651
- Khalighi, A., Behdani, R., and Kouhestani, S. (2016). Probiotics: a comprehensive review of their classification, mode of action and role in human nutrition. *Probiot. Prebiot. Hum. Nutr. Health* 10:63646. doi: 10.5772/63646
- Kim, J. A., Bayo, J., Cha, J., Choi, Y. J., Jung, M. Y., Kim, D. H., et al. (2019). Investigating the probiotic characteristics of four microbial strains with potential application in feed industry. *PLoS One* 14:e0218922. doi: 10.1371/ journal.pone.0218922
- Kim, S. Y., and Adachi, Y. (2007). Biological and genetic classification of canine intestinal lactic acid bacteria and bifidobacteria. *Microbiol. Immunol.* 51, 919– 928. doi: 10.1111/j.1348-0421.2007.tb03983.x
- Kuczynski, J., Lauber, C. L., Walters, W. A., Parfrey, L. W., Clemente, J. C., Gevers, D., et al. (2012). Experimental and analytical tools for studying the human microbiome. *Nat. Rev. Genet.* 13, 47–58. doi: 10.1038/nrg3129
- Kumar, M., Behare, P. V., Mohania, D., Arora, S., Kaur, A., and Nagpal, R. (2009). Health-promoting probiotic functional foods. *Focus Diet. Fibres* 20, 1–5.
- Kumar, M., Kumar, A., Nagpal, R., Mohania, D., Behare, P., Verma, V., et al. (2010). Cancer-preventing attributes of probiotics: an update. *Int. J. Food Sci. Nutr.* 61, 473–496. doi: 10.3109/09637480903455971
- Kumar, M., Verma, V., Nagpal, R., Kumar, A., Behare, P., Singh, B., et al. (2012). Anticarcinogenic effect of probiotic fermented milk and chlorophyllin on aflatoxin-B 1-induced liver carcinogenesis in rats. *Br. J. Nutr.* 107, 1006–1016. doi: 10.1017/S0007114511003953
- Kumar, S., Stecher, G., and Tamura, K. (2016). MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. *Mol. Biol. Evol.* 33, 1870–1874. doi: 10.1093/molbev/msw054
- Lamendella, R., Santo Domingo, J. W., Kelty, C., and Oerther, D. B. (2008). Bifidobacteria in feces and environmental waters. *Appl. Environ. Microbiol.* 74, 575–584. doi: 10.1128/AEM.01221-07
- Lane, D. (1991). "16S/23S rRNA sequencing," in Nucleic Acid Techniques in Bacterial Systematics, eds E. Stackebrandt and M. Goodfellow (New York, NY: John Wiley and Sons), 115–175.
- Lee, S. K., Yang, K. M., Cheon, J. H., Kim, T. I., and Kim, W. H. (2012). [Anti-inflammatory mechanism of Lactobacillus rhamnosus GG in

lipopolysaccharide- stimulated HT-29 cell]. Korean J. Gastroenterol. 60, 86–93. doi: 10.4166/kjg.2012.60.2.86

- Liong, M. T., and Shah, N. P. (2005). Acid and bile tolerance and cholesterol removal ability of lactobacilli strains. J. Dairy Sci. 88, 55–66. doi: 10.3168/jds. S0022-0302(05)72662-X
- Loh, G., and Blaut, M. (2012). Role of commensal gut bacteria in inflammatory bowel diseases. *Gut Microbes* 3, 544–555. doi: 10.4161/gmic.22156
- Manoj, K., Dheeraj, M., Devastotra, P., Behare, P., Ravinder, N., Ashok, K., et al. (2009). A probiotic fermented milk prepared by mixed culture reduces pathogen shedding and alleviates disease signs in rats challenged with pathogens. *Int. J. Probiot. Prebiot.* 4, 211–218.
- McClatchey, K. D. (2002). Clinical Laboratory Medicine. Philadelphia, PA: Lippincott Williams & Wilkins.
- McFarland, L. V. (2020). Efficacy of single-strain probiotics versus multi-strain mixtures: systematic review of strain and disease specificity. *Dig. Dis. Sci.* doi: 10.1007/s10620-020-06244-z [Epub ahead of print].
- Michail, S., Sylvester, F., Fuchs, G., and Issenman, R. (2006). Clinical efficacy of probiotics: review of the evidence with focus on children. J. Pediatr. Gastroenterol. Nutr. 43, 550–557.
- Nagata, S., Asahara, T., Wang, C., Suyama, Y., Chonan, O., Takano, K., et al. (2016). The effectiveness of *Lactobacillus* beverages in controlling infections among the residents of an aged care facility: a randomized placebo-controlled double-blind trial. *Ann. Nutr. Metab.* 68, 51–59. doi: 10.1159/000442305
- Nagpal, R., Kumar, A., Kumar, M., Behare, P. V., Jain, S., and Yadav, H. (2012). Probiotics, their health benefits and applications for developing healthier foods: a review. *FEMS Microbiol. Lett.* 334, 1–15. doi: 10.1111/j.1574-6968.2012. 02593.x
- Navas-Molina, J. A., Peralta-Sánchez, J. M., González, A., Mcmurdie, P. J., Vázquez-Baeza, Y., Xu, Z., et al. (2013). Advancing our understanding of the human microbiome using QIIME. *Methods Enzymol.* 531, 371–444. doi: 10.1016/B978-0-12-407863-5.00019-8
- Neveling, D. P., Van Emmenes, L., Ahire, J. J., Pieterse, E., Smith, C., and Dicks, L. M. T. (2017). Safety assessment of antibiotic and probiotic feed additives for *Gallus gallus* domesticus. *Sci. Rep.* 7:12767. doi: 10.1038/s41598-017-1 2866-7
- Podolsky, S. H. (2012). Metchnikoff and the microbiome. *Lancet* 380, 1810–1811. doi: 10.1016/S0140-6736(12)62018-2
- Rao, D., Le, T., and Bhushan, V. (2007). First aid for the USMLE step 1 2008. New York, NY: McGraw-Hill Medical.
- Richter, M., Rosselló-Móra, R., Oliver Glöckner, F., and Peplies, J. (2015). JSpeciesWS: a web server for prokaryotic species circumscription based on pairwise genome comparison. *Bioinformatics* 32, 929–931. doi: 10.1093/ bioinformatics/btv681
- Ripamonti, B., Agazzi, A., Bersani, C., De Dea, P., Pecorini, C., Pirani, S., et al. (2011). Screening of species-specific lactic acid bacteria for veal calves multistrain probiotic adjuncts. *Anaerobe* 17, 97–105. doi: 10.1016/j.anaerobe.2011. 05.001
- Ritchie, L. E., Steiner, J. M., and Suchodolski, J. S. (2008). Assessment of microbial diversity along the feline intestinal tract using 16S rRNA gene analysis. *FEMS Microbiol. Ecol.* 66, 590–598. doi: 10.1111/j.1574-6941.2008.00609.x
- Rognes, T., Flouri, T., Nichols, B., Quince, C., and Mahé, F. (2016). VSEARCH: a versatile open source tool for metagenomics. *PeerJ* 4:e2584. doi: 10.7717/peerj. 2584
- Rowe, J., Choct, M., Brown, W., and Day, K. (1997). Variation in the carbohydrate composition of dog food. *Recent Adv. Anim. Nutr. Aust.* 1997:242.
- Saarela, M., Mogensen, G., Fonden, R., Matto, J., and Mattila-Sandholm, T. (2000). Probiotic bacteria: safety, functional and technological properties. *J. Biotechnol.* 84, 197–215. doi: 10.1016/S0168-1656(00)00375-8
- Seemann, T. (2014). Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30, 2068–2069. doi: 10.1093/bioinformatics/btu153
- Sharma, G., and Im, S. H. (2018). Probiotics as a potential immunomodulating pharmabiotics in allergic diseases: current status and future prospects. *Allergy Asthma Immunol. Res.* 10, 575–590. doi: 10.4168/aair.2018.10. 6.575

- Shin, D., Chang, S. Y., Bogere, P., Won, K., Choi, J. Y., Choi, Y. J., et al. (2019). Beneficial roles of probiotics on the modulation of gut microbiota and immune response in pigs. *PLoS One* 14:e0220843. doi: 10.1371/journal.pone.0220843
- Shokryazdan, P., Faseleh Jahromi, M., Liang, J. B., and Ho, Y. W. (2017). Probiotics: from isolation to application. J. Am. Coll. Nutr. 36, 666–676. doi: 10.1080/ 07315724.2017.1337529
- Silva, B. C., Jung, L. R., Sandes, S. H., Alvim, L. B., Bomfim, M. R., Nicoli, J. R., et al. (2013). In vitro assessment of functional properties of lactic acid bacteria isolated from faecal microbiota of healthy dogs for potential use as probiotics. *Benef. Microbes* 4, 267–275. doi: 10.3920/BM2012.0048
- Silva, M., Jacobus, N. V., Deneke, C., and Gorbach, S. L. (1987). Antimicrobial substance from a human Lactobacillus strain. *Antimicrob. Agents Chemother*. 31, 1231–1233. doi: 10.1128/AAC.31.8.1231
- Singh, S., Bhatia, R., Singh, A., Singh, P., Kaur, R., Khare, P., et al. (2018). Probiotic attributes and prevention of LPS-induced pro-inflammatory stress in RAW264.7 macrophages and human intestinal epithelial cell line (Caco-2) by newly isolated Weissella cibaria strains. *Food Funct.* 9, 1254–1264. doi: 10.1039/C7FO00469A
- Song, D., Ibrahim, S., and Hayek, S. (2012). Recent application of probiotics in food and agricultural science. *Probiotics* 10, 1–34.
- Suchodolski, J. S., Camacho, J., and Steiner, J. M. (2008). Analysis of bacterial diversity in the canine duodenum, jejunum, ileum, and colon by comparative 16S rRNA gene analysis. *FEMS Microbiol. Ecol.* 66, 567–578. doi: 10.1111/j. 1574-6941.2008.00521.x
- Tagg, J. R., and McGiven, A. R. (1971). Assay system for bacteriocins. Appl. Microbiol. 21:943. doi: 10.1128/AM.21.5.943-943.1971
- Tamura, K., and Nei, M. (1993). Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. *Mol. Biol. Evol.* 10, 512–526.
- Tang, Y., Manninen, T. J., and Saris, P. E. (2012). Dominance of Lactobacillus acidophilus in the facultative jejunal Lactobacillus microbiota of fistulated beagles. Appl. Environ. Microbiol. 78, 7156–7159. doi: 10.1128/AEM.01975-12
- Tao, Y., Drabik, K. A., Waypa, T. S., Musch, M. W., Alverdy, J. C., Schneewind, O., et al. (2006). Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. *Am. J. Physiol. Cell Physiol.* 290, C1018–C1030. doi: 10.1152/ajpcell.00131.2005
- Yadav, H., Jain, S., and Sinha, P. R. (2008). Oral administration of dahi containing probiotic *Lactobacillus acidophilus* and *Lactobacillus casei* delayed the progression of streptozotocin-induced diabetes in rats. *J. Dairy Res.* 75, 189–195. doi: 10.1017/S0022029908003129
- Yan, F., Cao, H., Cover, T. L., Whitehead, R., Washington, M. K., and Polk, D. B. (2007). Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. *Gastroenterology* 132, 562–575. doi: 10.1053/ j.gastro.2006.11.022
- Zhang, L., Li, N., Des Robert, C., Fang, M., Liboni, K., Mcmahon, R., et al. (2006). Lactobacillus rhamnosus GG decreases lipopolysaccharide-induced systemic inflammation in a gastrostomy-fed infant rat model. J. Pediatr. Gastroenterol. Nutr. 42, 545–552. doi: 10.1097/01.mpg.0000221905.68781.4a
- Zitomersky, N. L., Atkinson, B. J., Franklin, S. W., Mitchell, P. D., Snapper, S. B., Comstock, L. E., et al. (2013). Characterization of adherent bacteroidales from intestinal biopsies of children and young adults with inflammatory bowel disease. *PLoS One* 8:e63686. doi: 10.1371/journal.pone.0063686

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Jang, Son, Kim, Jung, Choi, Kim, Lee, Shin and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.